MDM2 has been implicated in the development of resistance to certain chemotherapeutic agents. The overexpression of MDM2 can protect tumor cells from drug-induced apoptosis by inhibiting p53, allowing cancer cells to survive and continue proliferating despite treatment. This highlights the importance of considering MDM2 status in the design of effective treatment regimens and the development of MDM2 inhibitors as potential adjuvants in cancer therapy.
